Show simple item record

dc.contributor.authorAlvarez, A. 
dc.contributor.authorBernal, María J
dc.contributor.authorFradejas, Isabel
dc.contributor.authorMartin-Ramirez, Alexandra 
dc.contributor.authorMd Yusuf, Noor Azian
dc.contributor.authorLanza-Suarez, Marta 
dc.contributor.authorHisam, Shamilah
dc.contributor.authorPérez de Ayala, Ana
dc.contributor.authorRubio Muñoz, Jose Miguel 
dc.date.accessioned2021-01-21T08:45:33Z
dc.date.available2021-01-21T08:45:33Z
dc.date.issued2021-01-06
dc.identifier.citationMalar J . 2021 Jan 6;20(1):16es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11641
dc.description.abstractThe emergence and spread of anti-malarial resistance continues to hinder malaria control. Plasmodium falciparum, the species that causes most human malaria cases and most deaths, has shown resistance to almost all known anti-malarials. This anti-malarial resistance arises from the development and subsequent expansion of Single Nucleotide Polymorphisms (SNPs) in specific parasite genes. A quick and cheap tool for the detection of drug resistance can be crucial and very useful for use in hospitals and in malaria control programmes. It has been demonstrated in different contexts that genotyping by Kompetitive Allele Specific PCR (KASP), is a simple, fast and economical method that allows a high-precision biallelic characterization of SNPs, hence its possible utility in the study of resistance in P. falciparum. Three SNPs involved in most cases of resistance to the most widespread anti-malarial treatments have been analysed by PCR plus sequencing and by KASP (C580Y of the Kelch13 gene, Y86N of the Pfmdr1 gene and M133I of the Pfcytb gene). A total of 113 P. falciparum positive samples and 24 negative samples, previously analysed by PCR and sequencing, were selected for this assay. Likewise, the samples were genotyped for the MSP-1 and MSP-2 genes, and the Multiplicity of Infection (MOI) and parasitaemia were measured to observe their possible influence on the KASP method. The KASP results showed the same expected mutations and wild type genotypes as the reference method, with few exceptions that correlated with very low parasitaemia samples. In addition, two cases of heterozygotes that had not been detected by sequencing were found. No correlation was found between the MOI or parasitaemia and the KASP values of the sample. The reproducibility of the technique shows no oscillations between repetitions in any of the three SNPs analysed. The KASP assays developed in this study were efficient and versatile for the determination of the Plasmodium genotypes related to resistance. The method is simple, fast, reproducible with low cost in personnel, material and equipment and scalable, being able to core KASP arrays, including numerous SNPs, to complete the main pattern of mutations associated to P. falciparum resistance.es_ES
dc.description.sponsorshipThis work was funded by projects PI17/01791 and PI17CIII/00035 from the Instituto de Salud Carlos III (Ministry of Science and Innovation) and cofounded by the European Regional Development Fund. AMR is financed with an ISCIII- RIO HORTEGA contract (AESI RRHH-2017) from the Instituto de Salud Carlos III (Ministry of Science and Innovation). MJB is financed with a project associated contract from the Instituto de Salud Carlos III (Ministry of Science and Innovation)es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPlasmodium falciparumes_ES
dc.subjectKASPes_ES
dc.subjectResistancees_ES
dc.subjectSNPses_ES
dc.subjectK13es_ES
dc.subjectMDRes_ES
dc.subjectCytbes_ES
dc.titleKASP: a genotyping method to rapid identification of resistance in Plasmodium falciparum.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33407529es_ES
dc.format.volume20es_ES
dc.format.number1es_ES
dc.format.page16es_ES
dc.identifier.doi10.1186/s12936-020-03544-7es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1475-2875es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12936-020-03544-7es_ES
dc.identifier.journalMalaria journales_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/01791es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17CIII/00035es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional